4C supply deal has nothing to do with the deal that was done with Lemaitre, The deal with 4C was to supply tissue not products (ex Cardiocel) in 3 years time manufacturing will be retained minus the products that were sold to Lemaitre, so company will be making the TAVR and any new products that they come up with.
I believe the 3 years limit for Admedus to manufacture for Lemaitre was set by Admedus, this way they can free up the manufacturing capacity to make the TAVR and ??????
DYOR
TAVR/TMVR market projected to reach $8B by 2023, page-17
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.82 |
Change
-1.080(9.91%) |
Mkt cap ! $209.2M | |||
| Open | High | Low | Value | Volume |
| $10.50 | $10.79 | $9.30 | $1.212M | 122.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 219 | $9.82 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.00 | 250 | 1 |
View Market Depth
| Last trade - 14.28pm 06/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |